Healthcare professionals, play a crucial role in addressing the disparities in kidney donation and transplantation among Black patients. A conversation between doctors and donors provided…
(HealthDay News) — Racial and ethnic disparities are seen in the use of obesity-management medications, according to a study published online Dec. 17 in the…
(HealthDay News) — Three of four patients stop taking Ozempic or Wegovy two years after being prescribed the blockbuster drugs for weight loss, a new…
A recent study involving 50,000 patients has shed light on the intricate relationship between HbA1c levels, a key marker of long-term blood sugar control, and…
(HealthDay News) — The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has found. Zepbound reduced the…
(HealthDay News) — The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare…
(HealthDay News) — Add Alzheimer’s disease to the list of conditions that might benefit from the revolutionary diabetes drug Ozempic, a new study says. People…
(HealthDay News) — A higher body roundness index (BRI) trajectory is associated with an increased risk for cardiovascular disease (CVD), according to a study published…
(HealthDay News) — During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced tough questions over the company’s high…
(HealthDay News) — Initially approved to treat type 2 diabetes, Ozempic and Mounjaro also can help people with type 1 diabetes lose weight and control their blood…